A Khavinson-class prostate bioregulator. Marketed for prostate function and benign prostatic hyperplasia. As with the whole class, the evidence is Russian-language, unreplicated, and does not meet the standard applied elsewhere in this database.
Peptide bioregulators are built on a specific claim: that very short peptides extracted from — or synthesised to match — a particular organ can travel to that same organ and restore its normal function as it ages. Prostamax is the prostate version, promoted for urinary symptoms and prostate health in older men. The proposed route is direct interaction with DNA to switch tissue-specific genes back on. That mechanism has been demonstrated to the satisfaction of the group that proposed it and essentially nobody else.
A prostate-derived peptide preparation with a corresponding synthetic short peptide, reported by the originating group to influence prostatic epithelial function. It sits adjacent to the older prostate extract Vitaprost, which has a somewhat larger Russian clinical literature. The class hypothesis holds that di-, tri- and tetrapeptides penetrate cell and nuclear membranes and bind directly to specific promoter sequences in double-stranded DNA, modulating tissue-specific transcription — a mechanism supported by molecular modelling and gel-shift work from the originating institute but not independently corroborated. Products are marketed in two chemically distinct forms: "Cytomax" preparations, which are peptide fractions extracted from the corresponding animal organ, and "Cytogen" preparations, which are defined synthetic short peptides. Published clinical evaluation is limited to small Russian studies, generally without blinding, placebo control or independent statistical review.
Research areas
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| 10 mg daily as an extract capsule, or 100–200 mcg daily for the synthetic peptide form, taken as a 10–30 day courseThis describes what is marketed, not a validated regimen. No dose-finding study has been published. | Russian supplier protocol |
Small Russian studies from the originating institute. No registered Western trials, no independent replication, and no published randomised placebo-controlled evidence meeting international standards.
No. Alpha blockers and 5-alpha reductase inhibitors have substantial randomised trial evidence for urinary symptoms. Prostamax has none of that, and urinary retention or an unexamined rising PSA are not things to manage with a supplement.
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →